AC Immune
Kerstin Fabbri (Klinkert) has a strong background in cell and developmental biology, with experience in various research positions in both academic and industry settings. Kerstin has conducted preclinical research for medical devices in assisted reproductive technologies, investigated polarization mechanisms in embryos, studied cell polarization in kidney organoids, and explored the role of macrophages in wound healing and cardiac tissue repair. Kerstin has expertise in live cell imaging, genome editing, protein interaction assays, and quality control testing.
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.